💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Delavirdine Mesylate

CHEMBL929 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
552.7 g/mol
LogP
—
Phase
4

The mesylate salt form of delavirdine, a first-generation NNRTI used in combination antiretroviral regimens for HIV-1 infection. It requires multiple daily doses and has significant drug interactions due to CYP3A4 inhibition.

Moleküler Ağırlık

552,7000 g/mol

TPSA

182,00 Ų

Etki Mekanizması

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C22H28N6O3S.CH4O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-5(2,3)4/h4-8,13-15,24-26H,9-12H2,1-3H3;1H3,(H,2,3,4)

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H32N6O6S2

                    

                    
                    

                        
HBD / HBA

                        
4 / 10

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
6

                    

                    
                    
                    

                        
Ağır Atomlar

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
The mesylate salt form of delavirdine, a first-generation NNRTI used in combination antiretroviral regimens for HIV-1 infection. It requires multiple daily doses and has significant drug interactions due to CYP3A4 inhibition.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Delavirdine Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL929.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 441386.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.